An Efficacy and Safety Study of Palovarotene for the Treatment of MO



Status:Recruiting
Healthy:No
Age Range:2 - 14
Updated:3/27/2019
Start Date:April 20, 2018
End Date:February 2021
Contact:Clementia Call Center (US/Canada Only)
Email:ClinicalTrials@clementiapharma.com
Phone:1-800-750-8710

Use our guide to learn which trials are right for you!

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Palovarotene in Subjects With Multiple Osteochondromas

This is a randomized, double-blind, placebo-controlled study comparing the safety and
efficacy of 2 dosage regimens of palovarotene versus placebo in preventing disease
progression in pediatric subjects with multiple osteochondromas (MO).

Multiple osteochondromas is a rare condition where children develop multiple benign
cartilage-capped bony tumors called osteochondromas on bones throughout the body, resulting
in pain, deformity, limb length discrepancy, disability, and eventually arthritis and
possible malignancy. The primary objective is to compare the efficacy of two dosage regimens
of palovarotene with placebo to prevent the formation of new osteochondromas in pediatric MO
subjects with exostosin 1 or exostosin 2 gene mutations. Osteochondroma formation will be
assessed by whole body magnetic resonance imaging (MRI). Secondary efficacy objectives are to
compare the effect of palovarotene on the volume of osteochondromas as assessed by MRI; and
on the annualized rate of new or worsening deformities and MO-related surgeries. The overall
safety of palovarotene and the effects of palovarotene on linear growth, bone growth plates,
bone mineral density, quality of life, and pain due to osteochondromas will also be studied.

Key Inclusion Criteria:

- Written, signed, and dated informed subject/parent consent and age-appropriate assent
(performed according to local regulations).

- A clinical diagnosis of MO with disease-causing exostosin 1 or 2 gene mutations.

- Male or female from 2 to 14 years of age.

- Female subjects must be premenarchal at screening.

- A bone age at screening of 14 years or less.

- Symptomatic MO, defined as five or more clinically-evident osteochondromas and a new
or enlarged osteochondroma that occurred in the preceding 12 months, five or more
clinically-evident osteochondromas and the presence of a painful osteochondroma, a
skeletal deformity, a joint limitation, or prior surgery for a MO-related
complication.

- The ability to undergo whole body MRI with or without sedation/general anesthesia.

- Use of two effective methods of birth control during treatment, and for 1 month after
treatment discontinuation, unless committed to true abstinence from heterosexual sex.
Sexually active females of child-bearing potential must also agree to start effective
methods of birth control at screening.

Key Exclusion Criteria:

- Weight under 10 kg.

- Other syndromic conditions such as Langer-Giedion or Potocki-Shaffer.

- Any subject with neurologic signs suggestive of spinal cord impingement.

- Concomitant medications that are strong inhibitors or inducers of cytochrome P450 3A4
activity.

- Amylase or lipase >2 times the above the upper limit of normal (>2×ULN) or with a
history of chronic pancreatitis.

- Elevated aspartate aminotransferase or alanine aminotransferase above 2.5×ULN.

- Any surgical implant that is contraindicated for MRI.
We found this trial at
13
sites
Sacramento, California 95817
Principal Investigator: Michelle James, MD
Phone: 916-453-2136
?
mi
from
Sacramento, CA
Click here to add this to my saved trials
3400 N Charles St
Baltimore, Maryland 21205
410-516-8000
Principal Investigator: Nara Sobreira, MD, PhD
Phone: 410-502-7525
Johns Hopkins University The Johns Hopkins University opened in 1876, with the inauguration of its...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
300 Longwood Ave
Boston, Massachusetts 02115
(617) 355-6000
Principal Investigator: Christina Jacobsen, MD
Phone: 617-919-2867
Boston Children's Hospital Boston Children's Hospital is a 395-bed comprehensive center for pediatric health care....
?
mi
from
Boston, MA
Click here to add this to my saved trials
Chicago, Illinois 60707
Principal Investigator: Jeffrey Ackman, MD
Phone: 773-385-5532
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Houston, Texas 77030
Principal Investigator: Ernest Conrad, MD
Phone: 713-704-2639
?
mi
from
Houston, TX
Click here to add this to my saved trials
Los Angeles, California 90027
Principal Investigator: Vernon T Tolo, MD
Phone: 323-361-2843
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19410
Principal Investigator: Bethany Lipa, MD
Phone: 215-430-4239
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19104
Principal Investigator: Michael A Levine, MD
Phone: 267-426-7482
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Portland, Oregon 97239
Principal Investigator: Krister Freese, MD
Phone: 503-221-3471
?
mi
from
Portland, OR
Click here to add this to my saved trials
200 1st Street Southwest
Rochester, Minnesota 55905
Principal Investigator: Robert Pignolo, MD
Phone: 507-266-7837
?
mi
from
Rochester, MN
Click here to add this to my saved trials
San Francisco, California 94143
Principal Investigator: Jessica Tenney, MD
Phone: 415-502-2425
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
West Palm Beach, Florida 33040
Principal Investigator: David Feldman, MD
Phone: 561-531-1553
?
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
Westmead, New South Wales
Principal Investigator: Andreas Zankl, MD
?
mi
from
Westmead,
Click here to add this to my saved trials